Ghrelin in Alzheimer's disease: Pathologic roles and therapeutic implications

Ageing Res Rev. 2019 Nov:55:100945. doi: 10.1016/j.arr.2019.100945. Epub 2019 Aug 18.

Abstract

Ghrelin, which has many important physiological roles, such as stimulating food intake, regulating energy homeostasis, and releasing insulin, has recently been studied for its roles in a diverse range of neurological disorders. Despite the several functions of ghrelin in the central nervous system, whether it works as a therapeutic agent for neurological dysfunction has been unclear. Altered levels and various roles of ghrelin have been reported in Alzheimer's disease (AD), which is characterized by the accumulation of misfolded proteins resulting in synaptic loss and cognitive decline. Interestingly, treatment with ghrelin or with the agonist of ghrelin receptor showed attenuation in several cases of AD-related pathology. These findings suggest the potential therapeutic implications of ghrelin in the pathogenesis of AD. In the present review, we summarized the roles of ghrelin in AD pathogenesis, amyloid beta (Aβ) homeostasis, tau hyperphosphorylation, neuroinflammation, mitochondrial deficit, synaptic dysfunction and cognitive impairment. The findings from this review suggest that ghrelin has a novel therapeutic potential for AD treatment. Thus, rigorously designed studies are needed to establish an effective AD-modifying strategy.

Keywords: Alzheimer’s disease; Amyloid beta; Ghrelin; Mitochondrial deficits; Neuroinflammation; Tau.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Ghrelin / metabolism*
  • Humans
  • Mitochondria / metabolism
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Ghrelin
  • tau Proteins